No Data
No Data
Baiyang Pharmaceutical: 2024 Semi-Annual Report Summary
Baiyang Pharmaceutical: 2024 Semi-Annual Report
Baiyang Pharmaceutical (301015.SZ) released its performance for the first half of the year, with a net income of 0.369 billion yuan, an increase of 21.89%.
Baiyang Pharmaceutical (301015.SZ) released its 2024 interim report, with a revenue of 35.95...
Qingdao Baheal Medical (SZSE:301015) Might Become A Compounding Machine
Baoyang Pharmaceutical (301015.SZ) plans to lease some of the buildings located at No.88 Tongbai Road, Building 1, Shibei District, Qingdao City, Shandong Province, from its controlling shareholder.
On August 8th, Gelonhui reported that Bayang Pharmaceuticals (301015.SZ) announced that in order to meet the business development and daily management needs of the company and its subsidiaries, the company and its subsidiaries decided to lease part of the property located at No. 88 Tongbai Road, Shibei District, Qingdao City, Shandong Province, owned by its controlling shareholder, Bayang Pharmaceutical Group Co., Ltd. ('Bayang Group'), as the company and its subsidiaries' office space. The company and its subsidiaries are planning to lease a total area of 8,810.98 square meters, with a lease term of August 10, 2024 to December 31, 2027, including a rent-free period from August 10, 2024 to 2024.
Baoyang Pharmaceutical (301015.SZ): intends to purchase a 10% stake in the investment fund held by Baoyang Group
On August 8th, Gelonghui reported that Baiyang Medicine (301015.SZ) plans to use its own funds to purchase 10% of Baiyang Group's Baiyang Medicine Industry Investment Fund (limited partnership) (hereinafter referred to as the "investment fund") held in Mentougou District, Beijing, with a corresponding subscription amount of 25 million yuan to further optimize the company's global strategy layout. Since the target shares have not yet been fully paid, the transaction price for this transaction is RMB 0.00. After the transaction is completed, the company will have a subscribed investment of 74.5 million yuan, accounting for 29.80% of the total investment.
No Data